Novo Holdings (NASDAQ: COAG) details Hemab preferred stock stake

Rhea-AI Filing Summary

Novo Holdings A/S, a more than 10% owner of Hemab Therapeutics Holdings, Inc., filed an initial Form 3 to report its existing preferred stock holdings. The filing lists Series Seed, Series A, Series B and Series C Preferred Stock, each convertible into specified numbers of Common Stock.

According to the disclosure, each share of these preferred series will automatically convert into Common Stock on a 22-for-1 basis immediately prior to the closing of Hemab’s initial public offering for no additional consideration and with no expiration date. The reported positions represent pre‑IPO economic exposure rather than new market transactions.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Novo Holdings A/S

Role null

Type	Security	Shares	Price	Value
holding	Series Seed Preferred Stock	--	--	--
holding	Series A Preferred Stock	--	--	--
holding	Series B Preferred Stock	--	--	--
holding	Series C Preferred Stock	--	--	--

Holdings After Transaction: Series Seed Preferred Stock — 513,546 shares (Direct, null); Series A Preferred Stock — 1,581,052 shares (Direct, null); Series B Preferred Stock — 1,366,662 shares (Direct, null); Series C Preferred Stock — 719,290 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Series C underlying common: 719,290 shares Series B underlying common: 1,366,662 shares Series A underlying common: 1,581,052 shares +2 more

5 metrics

Series C underlying common 719,290 shares Underlying Common Stock for Series C Preferred

Series B underlying common 1,366,662 shares Underlying Common Stock for Series B Preferred

Series A underlying common 1,581,052 shares Underlying Common Stock for Series A Preferred

Series Seed underlying common 513,546 shares Underlying Common Stock for Series Seed Preferred

Conversion ratio 22-for-1 Automatic conversion of each preferred share into Common Stock

Key Terms

Form 3, Series C Preferred Stock, initial public offering, automatic conversion

4 terms

Form 3 regulatory

"filed an initial Form 3 to report its existing preferred stock holdings"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Series C Preferred Stock financial

"The filing lists Series Seed, Series A, Series B and Series C Preferred Stock"

A Series C preferred stock is a specific class of ownership issued during a later funding round that gives holders priority over common shareholders for getting paid and receiving dividends, like having a reserved lane in traffic when money is distributed. It often includes agreed rights such as a fixed payout, protection against dilution, and the option to convert into common shares, so investors treat it as a mix of safety and upside potential.

initial public offering financial

"convert into Common Stock on a 22-for-1 basis immediately prior to the closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

automatic conversion financial

"will automatically convert into shares of Common Stock on a 22-for-1 basis"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Novo Holdings A/S

(Last) (First) (Middle)

TUBORG HAVNEVEJ 19

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

DENMARK

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2026

3. Issuer Name and Ticker or Trading Symbol
Hemab Therapeutics Holdings, Inc. [ COAG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series Seed Preferred Stock	(1)	(1)	Common Stock	513,546	(1)	D
Series A Preferred Stock	(1)	(1)	Common Stock	1,581,052	(1)	D
Series B Preferred Stock	(1)	(1)	Common Stock	1,366,662	(1)	D
Series C Preferred Stock	(1)	(1)	Common Stock	719,290	(1)	D

Explanation of Responses:

1. Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock will automatically convert into shares of Common Stock on a 22-for-1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date.

	/s/ Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Novo Holdings A/S report in its Form 3 for COAG?

Novo Holdings A/S reports its existing holdings of Hemab Therapeutics preferred stock. The filing lists Series Seed, Series A, Series B and Series C Preferred Stock, each tied to specific numbers of underlying Common Stock shares before Hemab’s planned initial public offering.

Does the COAG Form 3 show Novo Holdings buying or selling shares?

The COAG Form 3 does not show new purchases or sales. It is an initial statement of beneficial ownership, disclosing Novo Holdings A/S’s existing preferred stock positions rather than reporting open‑market transactions or changes in its stake.

How will Novo Holdings’ Hemab preferred shares convert into COAG common stock?

Each share of Hemab’s Series Seed, Series A, Series B and Series C Preferred Stock will automatically convert into Common Stock on a 22-for-1 basis. This conversion occurs immediately before the closing of Hemab’s initial public offering, with no additional consideration required from holders.

What underlying common stock amounts are tied to Novo Holdings’ Hemab preferred shares?

Novo Holdings’ Hemab preferred holdings correspond to 719,290 underlying Common Stock shares for Series C, 1,366,662 for Series B, 1,581,052 for Series A and 513,546 for Series Seed, reflecting post‑conversion economic exposure before the IPO.

Do Hemab’s preferred shares reported by Novo Holdings have an expiration date?

The preferred shares reported by Novo Holdings have no expiration date. Each share of Series Seed, Series A, Series B and Series C Preferred Stock will automatically convert into Common Stock on a 22-for-1 basis immediately prior to the closing of Hemab’s initial public offering.